Record Revenue of EUR1.55 Million (+45.5% at Constant Forex)
Substantial Increase in Sales of the JAK2 Test: +169%
LUMINY, France, August 1 /PRNewswire-FirstCall/ -- IPSOGEN (Alternext -
FR0010626028 - ALIPS), a pioneer and key player in the development and
commercialization of molecular diagnostic tests for cancer, today announces
its revenue for its first half to 30 June 2008.
(in thousands of 30 June 2007 30 June 2008 Variation Variation
euros)* at constant
Revenue from products 879 1,415 +,61.2%
Revenue from services 218 137 -37.2%
Consolidated total 1,096 1,552 +41.6% + 45.6%
*non audited data, IFRS For the first half of 2008, revenue totaled EUR1.55 million versus EUR1.09 million for the same period of 2007, an increase of 45.5% at constant forex. At real currency rates, revenue growth was 41.6%.
Sales were up for IPSOGEN's entire portfolio of leukemia tests, but the JAK2 test recorded the most spectacular growth (+169%) despite the fact that this test only obtained CE certification towards the end of the period.
Vincent Fert, President and CEO, states: "We are very pleased with our achievements over this first half. The growth in activity was buoyant and in line with our expectations. These results confirm the potential of the JAK2 test in the diagnosis of myeloproliferative disorders and show that IPSOGEN's product portfolio is perfectly positioned to benefit from the molecular diagnosis of cancer market's very dynamic growth."
IPSOGEN develops and markets molecular diagnostic assays for patients
with cancer. With more than 60 products already used routinely in more than
50 countries for the diagnosis, prognosis and follow-up of thousands of
Copyright©2008 PR Newswire.
All rights reserved